Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02318901 (PembroMab) (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (PembroMab) (NCT02318901)

Trial Description
There will be two phase II cohorts for pembrolizumab (Keytruda®; Merck & Co., Inc.) plus trastuzumab (Herceptin®;Genentech, Inc.): one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) phase II arm will be for patients with HER2 overexpressing MBC. There will be two phase II cohorts for pembro plus cetuximab (Erbitux®; Eli Lilly and Company.): one cohort will be for patients with HNSCC, the other cohort will be for patients with K-ras, B-raf, N-ras wildtype metastatic CRC.

This trial is sponsored by Western Regional Medical Center. [1]

Study Data

  • Condition:
    • Advanced Cancer
    • Breast Cancer
    • Gastric Cancer
    • Esophageal Cancer
    • Colorectal Cancer
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 90
  • Start: October 2014
  • Estimated Primary Completion: October 2015
  • Last verified: April 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 31, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar